OBJECTIVE: @entity1499 ( @entity6822 ) is a commonly used disease-modifying antirheumatic drug in @entity5144 , but there is conflicting evidence to support its efficacy. METHODS: Within the Tight Control of @entity5144 (TICOPA) study, @entity1 were treated with @entity6822 as part of the tight control protocol or standard care. Outcomes were recorded at the 12-week visit, including joint counts, skin, nail, @entity4932 , dactylitis, and @entity1 -reported measures. RESULTS: Of the 206 @entity1 enrolled, 188 received @entity6822 in the first 12 weeks of the trial with 104 receiving a mean dose > 15 mg/week. The proportions of @entity1 achieving the American College of Rheumatology (ACR) outcomes at 12 weeks were ACR20 40.8%, ACR50 18.8%, and ACR70 8.6%, with 22.4% achieving minimal disease activity. Improvements were seen in psoriasis with 27.2% reaching a Psoriasis Area and Severity Index (PASI) 75. The proportion of @entity1 with dactylitis and Leeds dactylitis instrument (LDI) scores decreased significantly (62.7% decrease in @entity1 with dactylitis, median change LDI -59.7, -157.4 to -26.4, p = 0.033). The decrease in proportion of @entity1 with @entity4932 (25.7%) was significant, but the median change in @entity4932 score was 0. There was a trend to higher proportions of @entity1 receiving over 15 mg/week achieving ACR20, ACR50, and PASI75. CONCLUSION: Despite the open-label design of the data, improvements in multiple clinical outcomes were seen. The proportion of @entity1 reaching ACR20 in the TICOPA study was higher than in the @entity1499 in @entity5144 study (41% vs 34%), but no comparative data are available for other outcomes. There is a suggestion of a dose response, but this is hard to assess when @entity1 doing well may be maintained on lower doses.

@entity1499 Efficacy in the Tight Control in XXXX Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity5144 :: ('MESH:D015535', 'Disease') :: ['psoriatic arthritis', 'Psoriatic Arthritis'] @entity4932 :: ('MESH:D001171', 'Disease') :: ['enthesitis'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate']
@entity5144 :: (MESH:D015535,Disease) :: ['Psoriatic Arthritis']
